Entresto

DRUG9 trials

Conditions

Chronic Heart FailureCongestive Heart FailureDiabetesHeart FailureHypertensionHypertensive Heart DiseasePeripheral Arterial DiseaseType2 Diabetes

Phase 2

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

TerminatedNCT02636283

University of MinnesotaPeripheral Arterial Disease

Start: 2017-12-31End: 2018-11-01Updated: 2019-12-17

Role of ARNi in Ventricular Remodeling in Hypertensive LVH

CompletedNCT03553810

National Heart Centre SingaporeHypertensive Heart Disease

Start: 2019-04-12End: 2024-06-28Updated: 2025-06-26

Phase 4

Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis

CompletedNCT02754518

University of ChicagoHeart Failure

Start: 2016-04-30End: 2019-04-30Updated: 2021-01-29

Sacubitril-valsartan Versus Usual Anti-hypertensives in LVAD

WithdrawnNCT03279861

University of Maryland, BaltimoreCongestive Heart Failure, Hypertension

Start: 2017-11-30End: 2019-11-30Updated: 2023-05-06

The Effects of Neprilysin on Glucagon-like Peptide-1

CompletedNCT03717688

Nicolai Jacob Wewer AlbrechtsenDiabetes, Heart Failure

Start: 2018-05-17End: 2019-05-14Updated: 2019-07-08

Effect of Neprilysin on Glucagon-Like Peptide-1 in Patients With Type 2 Diabetes

CompletedNCT03893526

University of CopenhagenType2 Diabetes

Start: 2019-01-25End: 2021-03-01Updated: 2021-05-05

Unknown Phase

Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure

NCT03821701

First Affiliated Hospital Xi'an Jiaotong UniversityChronic Heart Failure

Start: 2018-06-01End: 2022-01-31Target: 340Updated: 2019-08-07

Special Drug Use Surveillance for Entresto Tablets

CompletedNCT04781881

Novartis PharmaceuticalsChronic Heart Failure

Start: 2021-03-04End: 2023-04-21Updated: 2023-05-06

Special Drug Use Surveillance of Entresto Tablets (Hypertension)

CompletedNCT05976230

Novartis PharmaceuticalsHypertension

Start: 2023-09-04End: 2025-05-29Updated: 2025-07-03

Related Papers

Sacubitril/valsartan versus valsartan in regressing myocardial fibrosis in hypertension: a prospective, randomized, open-label, blinded endpoint clinical trial protocol

Frontiers in Cardiovascular Medicine2023-08-2215 citations

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes

Diabetes Obesity and Metabolism2022-06-0916 citations

Circulating Concentrations of C-Type Natriuretic Peptides Increase with Sacubitril/Valsartan Treatment in Healthy Young Men

Clinical Chemistry2022-01-1710 citations